logo
  Join        Login             Stock Quote

Equity Research on Merck & Co. Inc. and Eli Lilly & Co. -- Major Drug Manufacturers Focusing on Widespread Afflictions

Tuesday, April 24, 2012 8:01 AM


http://media.marketwire.com/attachments/201106/79915_Shinesroomlogo15.06.11.JPGhttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=878308&ProfileId=051205&sourceType=1

NEW YORK, NY -- (Marketwire) -- 04/24/12 -- www.shinesrooms.com has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drug Manufacturers - Major industry and are offering free analytical research on Merck & Co. Inc. (NYSE: MRK) and Eli Lilly & Co. (NYSE: LLY). Register with us today at http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index to have free access to these research reports.

Much has been made of the adverse affect that patent expiries have had on many companies in the drug manufacturers - major industry as of late. Multi-billion dollar drugs have lost their exclusivity, and generic drug makers are reaping the rewards. Get your free reports on Merck & Co. Inc. and Eli Lilly & Co. at http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index. There is no commitment to join.

www.shinesrooms.com is the Ultimate Trading Environment for investors. If you are considering owning Merck & Co. Inc. and Eli Lilly & Co. then you should sign up for a free membership and our complimentary reports today at www.shinesrooms.com. Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

However, major drug manufacturers such as Merck & Co. Inc. and Eli Lilly & Co. have not been standing idly by. Several companies have been focusing on health disorders that affect a large number of the population, such as cancer, diabetes and Alzheimer's.

Merck recently entered into an agreement with Endocyte Inc. to develop and commercialize Endocyte's vintafolide (EC145). The candidate is being looked at in phase III trials for ovarian cancer as well as a Phase II trial for non-small-cell lung cancer. Merck & Co. Inc. report is accessible for free by registering today at http://www.shinesrooms.com/MerckandCoInc240412.pdf.

Addirionally, Eli Lilly has also been active recently, with the FDA approving its Alzheimer's related Amyvid offering. The company, in tandem with Walgreens, has also launched a diabetes awareness campaign aimed at educating people about hypoglycemia. Eli Lilly & Co. report is accessible for free by registering today at http://www.shinesrooms.com/EliLillyandCo240412.pdf.

The two Drug Manufacturers - Major stocks research reports are available for free by signing up now on www.shinesrooms.com.

About Shinesrooms.com
Shine's Rooms is the brainchild of David Shine, a 13-year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting-edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link http://www.shinesrooms.com/disclaimer.html.

Contact Person:

Michael Thomas Smith
Marketing Coordinator
info@shinesrooms.com


(Source: Market Wire )
(Source: Quotemedia)

Advertisement
Advertisement



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.